On the same day that House Speaker Nancy Pelosi, D-California, unveiled her plan to lower drug prices by giving the United States the ability for Medicare to negotiate certain drug prices and seek rebates from drug makers if their prices soar above inflation, a new AARP report shows that retail prices in 2017 were 2.1% above the general inflation rate and marked 12 straight years of price increases.
On the same day that House Speaker Nancy Pelosi, D-California, unveiled her plan to lower drug prices by giving the United States the ability for Medicare to negotiate certain drug prices and seek rebates from drug makers if their prices soar above inflation, a new AARP report shows that retail prices in 2017 were 2.1% above the general inflation rate and marked 12 straight years of price increases.
In the Pelosi drug plan, which will get a hearing in a subcommittee of the House Energy and Commerce next week, the secretary of HHS would be authorized annually to negotiate prices for up to 250 of the most costly drugs that lack a generic or biosimilar competitor, including both Part D and Part B. The maximum price would be determined using a blend of international prices and must not exceed 1.2 times the average price in Australia, Canada, France, Germany, Japan, and the United Kingdom. That is somewhat similar to a proposal from the Trump administration, and insulin would be included.
In addition, HHS will assign penalties to drug companies that refuse to negotiate, starting at 65% of sales for the drug at issue and rising from there; The New York Times notes that is even stiffer than what was proposed in the draft.
The plan, called HR 3, Lower Drug Costs Now Act of 2019, would cap what seniors pay out of pocket for their medications to $2000 a year. And it would require drug makers to pay rebates to Medicare if they hike their prices beyond the increase in inflation.
The plan was cheered by Ben Wakana, executive director of Patients For Affordable Drugs Now, who says, “Early details of HR 3 clearly deliver on the promise to break the monopoly pricing power of drug corporations by allowing Medicare to negotiate for lower prescription prices. Importantly, the legislation incorporates key bipartisan priorities like an International Pricing Index, caps on price increases, and an out-of-pocket limit for prescription drug spending."
Others are looking to see if the plan (even though it has close to no chance of being passed in the Senate) will boost the use of lower-cost biosimilars.
“All prescription drug pricing efforts can be improved and billions in savings can be realized by realigning Medicare policies to encourage patient use of lower-priced generics and biosimilars,” says a spokeswoman for the Association for Accessible Medicines. Likewise, the president of the Biosimilars Forum, Julie Reed, said any pending bill "needs to include policies that improve patients’ access to biosimilars, which analyses repeatedly show would save taxpayers and the health care system tens of billions of dollars."
Meanwhile, the latest AARP Rx Price Watch report finds that retail prices for widely used prescription drugs increased by an average of 4.2% in 2017, while the general inflation rate was 2.1%.
Leigh Purvis and Stephen W. Schondelmeyer, PharmD, PhD, authored the report, which says that the cost for 1 specialty medication used for chronic disease approached $20,000 in 2017. If the retail price changes for the medication had been limited to general inflation between 2006 and 2017, the price would have been $7263.
The report says that in 2017, the average annual retail cost for 754 brand name, generic, and specialty prescription drugs used to treat chronic conditions was almost $20,000 per year, or nearly 20% higher than the average Social Security retirement benefit ($16,848). The annual drug cost was also more than three-fourths of the median income for Medicare beneficiaries ($26,200) and almost one-third of the median US household income ($60,336), the AARP said.
“If these trends continue, older Americans will be unable to afford the prescription drugs that they need, leading to poorer health outcomes and higher health care costs in the future,” the report says.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.